SRRA Projected Dividend Yield

Sierra Oncology Inc ( NASDAQ : SRRA )

Sierra Oncology is a late stage drug biopharmaceutical company on a quest to deliver targeted therapies that treat cancer. Co.'s main focus is the development of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is an orally-bioavailable Janus kinase 1, Janus kinase 2 and Activin A receptor type 1 inhibitor with a mechanism of action, enabling it to potentially address all three hallmarks of disease in myelofibrosis: anemia of inflammation, constitutional symptoms and enlarged spleen. Co.'s portfolio also includes SRA737, a selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1, an emerging target for the treatment of cancer.

20 YEAR PERFORMANCE RESULTS